Mein Warenkorb

PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation)

Product Number/Spec
Price
Availability
Menge
EGI-HP2E3-25tests
$415.00
In Stock - Delivery in 2-3 business days
EGI-HP2E3-200tests
$2570.00
In Stock - Delivery in 2 weeks
Gesamtanzahl Product Amount$ 0

Product Details

  • Synonyms

    EGFRvIII

  • Source

    PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII, His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).

    Predicted N-terminus: Leu 25

    Request for sequence

  • Molecular Characterization

    EGFRvIII Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 42.2 kDa.

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Application

    Please note that this product is NOT compatible to streptavidin detection system.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • Bioactivity-Flow Cytometry

     EGFRvIII FACS

    5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

User Reviews
Publish Comment

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Background Introduction

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Frontier Progress

 
Drug Development Progress
  • English Name:

    Epidermal growth factor receptor variant III

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    14 Details

  • Highest R&D Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • FAQ
  • Hintergrund
Kontaktieren Sie uns